Clinical Trials Logo

Rhinoconjunctivitis clinical trials

View clinical trials related to Rhinoconjunctivitis.

Filter by:

NCT ID: NCT02075138 Completed - Rhinoconjunctivitis Clinical Trials

Grass Observational Study

Start date: April 2014
Phase: N/A
Study type: Observational

Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans, including asthma, allergic rhinitis, conjunctivitis and dermatitis. The purpose of the current study is to evaluate allergy symptoms and allergy medication in subjects with grass-related rhinoconjunctivitis.

NCT ID: NCT01949441 Completed - Rhinoconjunctivitis Clinical Trials

ToleroMune House Dust Mite (HDM) Tolerability Study

Start date: September 2013
Phase: Phase 2
Study type: Interventional

House Dust Mites (HDMs) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDMA in sensitised patients is associated with poorer lung function, greater medication requirements and more asthma symptoms as well as chronic rhinosinusitis symptoms. In contrast to other allergens, there is evidence that HDMA leads to the development of asthma, in addition to exacerbating pre-existing asthma in HDM-sensitised patients. ToleroMune House Dust Mite (TM-HDM), a combination of seven Synthetic Peptide Immuno-Regulatory Epitopes, is being developed for the treatment of HDM allergy. This study to assess the tolerability of ToleroMune House Dust Mite in subjects with controlled asthma and house dust mite-induced rhinoconjunctivitis.

NCT ID: NCT01949428 Completed - Rhinoconjunctivitis Clinical Trials

House Dust Mite Observational Study

Start date: September 2013
Phase: N/A
Study type: Observational

A Field Study to Observe Symptom Scores and Allergy Medication Usage in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis

NCT ID: NCT01949415 Completed - Rhinoconjunctivitis Clinical Trials

An Optional Investigation of Biomarkers of Efficacy

Start date: September 2013
Phase: N/A
Study type: Observational

House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDMA in sensitised patients is associated with poorer lung function, greater medication requirements and more asthma symptoms as well as chronic rhinosinusitis symptoms. In contrast to other allergens, there is evidence that HDMA leads to the development of asthma, in addition to exacerbating pre-existing asthma in HDM-sensitised patients. ToleroMune House Dust Mite (TM-HDM) is being developed for the treatment of HDM allergy. Study TH002 evaluated the efficacy, safety and tolerability of TM-HDM. This study will identify cellular, proteomic or genetic biomarkers of efficacy to TM-HDM treatment in TH002 study participants

NCT ID: NCT01923792 Completed - Rhinoconjunctivitis Clinical Trials

ToleroMune House Dust Mite Follow on Study

Start date: September 2013
Phase: N/A
Study type: Observational

House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDM allergens in sensitised patients is associated with poorer lung function, greater medication requirements and more asthma symptoms as well as chronic rhinosinusitis symptoms. In contrast to other allergens, there is evidence that HDMA leads to the development of asthma, in addition to exacerbating pre-existing asthma in HDM-sensitised patients. ToleroMune HDM is currently being developed for the treatment of HDM allergy. The Purpose of this optional observational follow-on study is to evaluate the continued efficacy of TM-HDM in HDM allergic subjects based on change in TRSS from TH002 baseline approximately two years after the completion of the baseline EEC visit in TH002 following challenge with HDM allergen in an EEC.

NCT ID: NCT01923779 Completed - Rhinoconjunctivitis Clinical Trials

ToleroMune Grass Follow on Study

Start date: May 2013
Phase: N/A
Study type: Observational

Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy. The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to Grass in the EEU among subjects who completed all dosing visits in study TG002 approximately one year after the start of treatment.

NCT ID: NCT01921257 Completed - Rhinoconjunctivitis Clinical Trials

Paediatric Safety Study in Cat-PAD

Start date: August 2013
Phase: Phase 2
Study type: Interventional

Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects

NCT ID: NCT01808768 Unknown status - Clinical trials for Allergic Conjunctivitis

Ocular Allergy Treatment Practical Impact Trial

(OAT-PIT)
Start date: April 2013
Phase: Phase 4
Study type: Interventional

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

NCT ID: NCT01734265 Completed - Allergy Clinical Trials

Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

Start date: November 2012
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.

NCT ID: NCT01720251 Completed - Allergic Rhinitis Clinical Trials

Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy

Start date: October 2012
Phase: Phase 2
Study type: Interventional

The main objective of the trial is to demonstrate the efficacy of a two months pre-seasonal treatment with AllerT 100 µg maintenance dose in reducing symptoms of allergic rhinoconjunctivitis during the following birch pollen season